rilvegostomig

ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
Clinical Trials Arena
Tue, 06/6/23 - 10:06 am
ASCO 2023
AstraZeneca
clinical trials
non-small cell lung cancer
rilvegostomig